Janet Woodcock, acting FDA commissioner (Bill Clark/CQ Roll Call via AP Images)

FDA’s do­mes­tic bio­phar­ma in­spec­tions re­turn to nor­mal as agency faces back­log of 8,000+

For the first time since March 2020, the FDA’s in­spec­tions of US-based bio­phar­ma sites have re­turned to nor­mal, FDA act­ing com­mis­sion­er Janet Wood­cock said Mon­day at a small busi­ness reg­u­la­to­ry event.

“I’m pleased to say that as of this month, we’ve be­gun tran­si­tion­ing back to stan­dard op­er­a­tions for do­mes­tic in­spec­tions while con­tin­u­ing to pri­or­i­tize mis­sion-crit­i­cal work for for­eign in­spec­tions,” Wood­cock said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.